CSL Limited Company Profile (ASX:CSL)

About CSL Limited (ASX:CSL)

CSL Limited logoCSL Limited is a biotherapeutics company that develops and delivers biotherapies. The Company's principal activities are research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. Its segments include CSL Behring, Seqirus and CSL Intellectual Property. The CSL Behring segment manufactures, markets and develops plasma therapies (plasma products and recombinants). The Seqirus segment manufactures and distributes non-plasma biotherapeutic products. Seqirus manufactures, sells and distributes a range of vaccines, antivenoms and other pharmaceutical products in Australia and New Zealand. It also manufactures and markets in vitro diagnostic products through Seqirus immunohematology. The CSL Intellectual Property segment is engaged in licensing of intellectual property generated by the Company to unrelated third parties. The Company has facilities in Australia, Germany, Switzerland, the United Kingdom and the United States.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: ASX:CSL
  • CUSIP: N/A
  • Web: www.csl.com.au/
Average Prices:
  • 50 Day Moving Avg: A$128.55
  • 200 Day Moving Avg: A$128.50
P/E:
  • Trailing P/E Ratio: 45.40
  • P/E Growth: 0.00
Dividend:
  • Dividend Yield: 1.0%
Profitability:
  • Net Margins: 16.35%
  • Return on Equity: 34.95%
  • Return on Assets: 12.30%
 

Frequently Asked Questions for CSL Limited (ASX:CSL)

What is CSL Limited's stock symbol?

CSL Limited trades on the ASX under the ticker symbol "CSL."

Who are some of CSL Limited's key competitors?

Who are CSL Limited's key executives?

CSL Limited's management team includes the folowing people:

  • Paul Perreault, Chief Executive Officer, Managing Director, Executive Director
  • David Mark Lamont, Chief Financial Officer
  • Gordon Naylor, President - Seqirus
  • Greg Boss, Executive Vice President, Legal and CSL Group General Counsel
  • Karen Etchberger, Executive Vice President - Quality and Business Services
  • Bob Repella, Executive Vice President - Global Commercial Operations
  • Val Romberg, Executive Vice President of Manufacturing and Planning
  • Alan J. Wills, Senior Vice President - Strategy and Business Development
  • Andrew Cuthbertson, Chief Scientific Officer, R&D Director
  • Laurie Cowan, Senior Vice President - Human Resources


MarketBeat Community Rating for CSL Limited (ASX CSL)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  108 (Vote Outperform)
Underperform Votes:  71 (Vote Underperform)
Total Votes:  179
MarketBeat's community ratings are surveys of what our community members think about CSL Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for CSL Limited (ASX:CSL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for CSL Limited (ASX:CSL)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for CSL Limited (ASX:CSL)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for CSL Limited (ASX:CSL)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for CSL Limited (ASX:CSL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for CSL Limited (ASX:CSL)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for CSL Limited (ASX:CSL)
Latest Headlines for CSL Limited (ASX:CSL)
Source:
DateHeadline
fool.com logoWhy the Starpharma Holdings Limited share price rocketed higher ... - Motley Fool Australia
www.fool.com.au - September 22 at 9:40 PM
fool.com logoIs the CSL Limited share price about to storm higher?
www.fool.com.au - September 19 at 10:37 PM
finance.yahoo.com logoCSL Behring Will Help Transform Biotech Education and Research with $4.92 Million Gift to Penn State
finance.yahoo.com - September 19 at 5:35 PM
businesswire.com logoSeqirus Donates Influenza Vaccine for Hurricane Harvey Relief in Texas - Business Wire (press release)
www.businesswire.com - September 15 at 11:04 PM
prnewswire.com logoCSL Behring Joins Together With Conference Attendees to Make Donation to IPOPI - PR Newswire (press release)
www.prnewswire.com - September 15 at 11:04 PM
prnewswire.com logoCSL Behring Announces FDA Approval of Privigen® [Immune Globulin Intravenous (Human), 10% Liquid] for the ... - PR Newswire (press release)
www.prnewswire.com - September 15 at 11:04 PM
bizjournals.com logoFDA approves CSL Behring drug for third use
www.bizjournals.com - September 15 at 6:01 PM
fool.com logoWhy the Mayne Pharma Group Ltd share price is climbing higher
www.fool.com.au - September 14 at 11:26 PM
finance.yahoo.com logoCSL Behring Announces FDA Approval of Privigen® for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults
finance.yahoo.com - September 14 at 11:26 PM
finance.yahoo.com logoCSL Behring Joins Together With Conference Attendees to Make Donation to IPOPI
finance.yahoo.com - September 14 at 6:25 PM
finance.yahoo.com logoSeqirus Receives FDA Approval of AFLURIA QUADRIVALENT® (Influenza Vaccine) for People Five Years of Age and Older in the U.S.
finance.yahoo.com - September 14 at 6:25 PM
finance.yahoo.com logoSeqirus Donates Influenza Vaccine for Hurricane Harvey Relief in Texas
finance.yahoo.com - September 13 at 6:52 PM
finance.yahoo.com logoCanadian Parents Willing to Vaccinate Their Infants with Adjuvanted Influenza Vaccine, Study Finds
finance.yahoo.com - September 11 at 6:12 PM
finance.yahoo.com logoNew Phase III Study Shows Significantly Greater Efficacy in Children 6-24 Months Who Receive Adjuvanted Influenza Vaccine (aQIV)
finance.yahoo.com - September 11 at 6:12 PM
fool.com logoCan expensive CSL Limited shares deliver capital growth in FY18?
www.fool.com.au - September 5 at 7:10 PM
finance.yahoo.com logoCSL Ltd. breached its 50 day moving average in a Bullish Manner : CSL-AU : September 5, 2017
finance.yahoo.com - September 5 at 3:31 AM
fool.com logo3 small-cap shares with strong growth potential - Motley Fool Australia
www.fool.com.au - September 4 at 10:28 PM
fool.com logoHidden beneath the flat ASX stock market is a whole other world of opportunity - Motley Fool Australia
www.fool.com.au - September 4 at 3:11 AM
fool.com logo2 top healthcare companies I'm watching like a hawk - Motley Fool Australia
www.fool.com.au - September 3 at 10:08 PM
finance.yahoo.com logoETFs with exposure to CSL Ltd. : August 29, 2017
finance.yahoo.com - August 29 at 10:58 PM
bizjournals.com logo$91M deal: CSL acquires stem cell gene therapy developer
www.bizjournals.com - August 28 at 5:24 PM
finance.yahoo.com logoCSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform
finance.yahoo.com - August 28 at 5:24 PM
finance.yahoo.com logo[$$] CSL Behring to Buy Biotech Startup Calimmune for $416 Million
finance.yahoo.com - August 28 at 5:24 PM
fool.com logoIs CSL Limited buying its way to growth? - Motley Fool Australia
www.fool.com.au - August 27 at 9:58 PM
fool.com logoWhy the Mayne Pharma Group Ltd share price fell 7% today | Motley ... - Motley Fool Australia
www.fool.com.au - August 25 at 3:51 AM
finance.yahoo.com logoCSL Ltd. :CSL-AU: Earnings Analysis: 2017 By the Numbers : August 22, 2017
finance.yahoo.com - August 22 at 11:11 PM
finance.yahoo.com logoCSL Ltd. :CSL-AU: Earnings Analysis: For the six months ended June 30, 2017 : August 23, 2017
finance.yahoo.com - August 22 at 11:11 PM
seekingalpha.com logoCSL Limited Leader In High Growth Plasma Sales To China
seekingalpha.com - August 22 at 6:10 PM
reuters.com logoAustralia shares end lower as caution prevails; NZ slightly down
www.reuters.com - August 21 at 4:50 AM
reuters.com logoAustralia shares fall on weaker financials, global cautious; NZ also down
www.reuters.com - August 20 at 11:48 PM
fool.com logoWhy the Primary Health Care Limited share price has sunk lower today - Motley Fool Australia
www.fool.com.au - August 18 at 4:52 AM
fool.com logoAre CSL Limited shares a buy after yesterday’s profit result?
www.fool.com.au - August 17 at 4:01 AM
finance.yahoo.com logoEdited Transcript of CSL.AX earnings conference call or presentation 16-Aug-17 1:00am GMT
finance.yahoo.com - August 16 at 5:59 PM
rttnews.com logoCSL FY Profit Rises
www.rttnews.com - August 15 at 11:18 PM
finance.yahoo.com logoCSL Limited -- Moody's takes rating action on CSL Limited
finance.yahoo.com - August 15 at 6:18 PM
finance.yahoo.com logoBerinert® Approved by Health Canada for the Treatment of Hereditary Angioedema (HAE) in Pediatric Patients
finance.yahoo.com - August 9 at 5:45 PM
businesswire.com logoSeqirus Announces Major Advances in Pandemic Preparedness ... - Business Wire (press release)
www.businesswire.com - August 8 at 4:00 AM
fool.com logoMayne Pharma Group Ltd shares sink on trading update - Motley Fool Australia
www.fool.com.au - August 8 at 4:00 AM
seekingalpha.com logoXencor's (XNCR) CEO Bassil Dahiyat on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 7 at 10:58 PM
finance.yahoo.com logoSeqirus Announces Major Advances in Pandemic Preparedness
finance.yahoo.com - August 7 at 5:58 PM
fool.com logoThink about this if you want to own shares forever - Motley Fool Australia
www.fool.com.au - August 4 at 12:00 AM
bizjournals.com logoGlobal Markets for Blood Plasma Products
www.bizjournals.com - August 1 at 6:14 PM
businesswire.com logoGlobal Hereditary Angioedema Market: Industry Analysis & Outlook (2017-2021) - Upcoming Novel Drugs to Drive ... - Business Wire (press release)
www.businesswire.com - July 31 at 10:31 PM
bizjournals.com logoGlobal Market for Blood Plasma Was Worth $16.8 Billion in 2016 - Expected to Reach $23.0 Billion in 2021
www.bizjournals.com - July 29 at 4:54 PM
fool.com logo2 ASX shares for a falling Aussie dollar - Motley Fool Australia
www.fool.com.au - July 28 at 7:25 PM
finance.yahoo.com logoHAEGARDA® (C1 Esterase Inhibitor Subcutaneous ) Now Available in the United States for Patients with Hereditary Angioedema
finance.yahoo.com - July 25 at 5:33 PM
fool.com logoHere's what has happened to the Australian Dollar (A$) - Motley Fool Australia
www.fool.com.au - July 24 at 10:19 PM
finance.yahoo.com logoETFs with exposure to CSL Ltd. : July 24, 2017
finance.yahoo.com - July 24 at 5:17 PM
seekingalpha.com logo3 Things In Biotech You Should Learn Today: July 22, 2017
seekingalpha.com - July 23 at 5:14 PM
prnewswire.com logoCSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) - PR Newswire (press release)
www.prnewswire.com - July 22 at 5:21 AM

Social

Social activity is not available for this stock.
This page was last updated on 9/23/2017 by MarketBeat.com Staff